EUCTR2017-003342-25-FR进行中（未招募）1 期
ong-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis - API-CAT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,722
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed Written Informed Consent
- •- Breast, prostate, colo-rectal cancer diagnosed histologically
- •- Active cancer defined as the presence of measurable disease or ongoing (or planned) chemotherapy, radiotherapy, hormonotherapy or targeted therapy at inclusion.
- •- Objectively documented index event of :
- •symptomatic or incidental proximal lower-limb, iliac, inferior cava vena DVT or symptomatic or incidental PE in a segmental or larger pulmonary artery
- •(1) Proximal DVT is defined as DVT that involves at least the popliteal vein or a more proximal vein, demonstrated by imaging with compression ultrasound (CUS), including grey-scale or color-coded Doppler, or ascending contrast venography or contrast enhanced computed tomography or magnetic resonance imaging.
- •(2) PE has to be demonstrated by imaging as follows:
- •an intraluminal filling defect in segmental or more proximal branches on contrast enhanced chest computed tomography or on computed tomography pulmonary angiography ; or
- •an intraluminal filling defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram; or
- •a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)
- •(3) Incidental VTE is defined as proximal DVT or PE detected by imaging incidentally when a patient undergoes imaging studies as standard of care for the management of his or her malignancy or other reasons but not for a VTE suspicion(e.g. cancer diagnosis or staging).
- •- 6 months of anticoagulant therapy at therapeutic dosage (whatever the drug and the dosing), or completed assigned a clinical trial study treatment, for the treatment of the index event; and patient still receiving anticoagulant treatment 6 months after occurrence or the VTE index event.
- •- No objectively documented symptomatic recurrence of VTE between the index event and randomization.
- •- Anticipated duration of anticoagulant treatment of at least 12 months at the time of randomization.
- •- Patient affiliated to social security for French centers.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1722
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- WOCBP who are unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides)] to avoid pregnancy for the entire study
- •- Women who are pregnant or breastfeeding
- •- Women with a positive pregnancy test on enrollment or prior to investigational product administration
- •- Isolated sub-segmental incidental or symptomatic PE without associated DVT
- •- Isolated distal DVT of the legs
- •- Isolated upper-extremity DVT or superior vena cava thrombosis
- •- Isolated visceral thrombosis
- •- Isolated catheter thrombosis
- •- Objectively documented symptomatic recurrence of VTE after the index event under anticoagulant treatment
- •- VTE during anticoagulant treatment given at therapeutic dosage
- •- Subjects with indications for long-term treatment with a VKA, such as:
- •Mechanical heart valve
- •Antiphospholipid syndrome
- •- Subjects with indication for long-term anticoagulation with a VKA or a DOAC at therapeutic dosage
- •- Conditions increasing the risk of serious bleeding
- •intracranial or intraocular bleeding within the 6 months ;
- •major surgery within 2 weeks prior to randomization;
- •- overt major bleeding at time of randomization.
- •- Life expectancy < 3 months
- •- Eastern Cooperative Oncology Group (ECOG) level 3 or 4
- •- Bacterial endocarditis
- •- Uncontrolled hypertension: systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg
- •- Platelet count <50,000/mm3;
- •- Creatinine clearance < 30 ml /min based on the Cockcroft Gault equation; (see Section 5.9.2);
- •- Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range
- •- Subjects requiring ASA >165 mg/day at randomization or thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor).
- •- Subjects requiring dual anti-platelet therapy (such as ASA plus clopidogrel or ASA plus ticlopidine) at randomization. Subjects who transition from dual antiplatelet therapy to monotherapy prior to randomization will be eligible for the trial.
- •- Concomitant use of strong inhibitors of both cytochrome P-450 3A4 and P Glycoprotein (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole) or strong inducers of both cytochrome P-450 3A4 and P Glycoprotein (e.g., rifampicin, carbamazepine, or phenytoin).
- •- Prisoners or subjects who are involuntarily incarcerated
- •- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
- •- Hypersensitivity to apixaban
- •- Subjects participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the coagulation system
研究者
相似试验
进行中（未招募）
1 期
ong-term treatment of cancer associated VTE: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisAny cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, afterat least 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and randomization.MedDRA version: 21.1Level: LLTClassification code 10076654Term: Cancer-associated thrombosisSystem Organ Class: 100000004864EUCTR2017-003342-25-GRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722
进行中（未招募）
不适用
ong-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label studyEUCTR2009-015336-15-DEDepartment of Vascular Medicine of the Academic Medical Center1,000
进行中（未招募）
不适用
ong-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label studyDeep venous thrombosis or pulmonary embolism in patients with cancerMedDRA version: 12.0Level: LLTClassification code 10066899Term: Venous thromboembolismEUCTR2009-015336-15-NLDepartment of Vascular Medicine of the Academic Medical Center1,000
进行中（未招募）
不适用
ong-term treatment for cancer patients with deep venous thrombosis or pulmonary embolism - NDVenous thromboembolism including deep vein thrombosis and pulmonary embolismMedDRA version: 9.1Level: HLTClassification code 10037379MedDRA version: 9.1Level: PTClassification code 10051055EUCTR2009-015336-15-ITIVERSITA` DEGLI STUDI G. D`ANNUNZIO CHIETI1,000
尚未招募
不适用
ong-term treatment of deep vein thrombosis or pulmonary embolism in patients with cancerpulmonary embolismdeep vein thrombosisvenous thromboembolismcancerkankerlongemboliediep veneuze tromboseveneuze trombo-embolieNL-OMON28644niversity Medical Center Groningen200